Ubitus K.K. to Showcase at VivaTech 2024, Highlighting Innovations in AIGC and Cloud Gaming
Ubitus K.K. (hereinafter Ubitus), a leading cloud gaming technology provider, is thrilled to announce its participation in Viva Technology 2024, Europe’s biggest startup and tech event, taking place from May 22nd to May 25th at Paris Expo Porte de Versailles. Visitors can explore Ubitus' innovative solutions at Booth D38 in the TTA Pavilion, Hall 1, where you can express your creativity through Ubitus’ AI solutions.
Innovative Demonstrations at the Ubitus Booth
Ubitus is excited to showcase its AI technologies that increase creativity and productivity for everyone, including the debut of Ubi-chan in French and UbiArt, its visual art AI generative tool. Ubi-chan, Ubitus' AI V-tuber, will engage with attendees, providing an interactive experience that highlights the capabilities of AI in entertainment. Additionally, Ubitus will unveil UbiArt at the event, featuring unique “local style models” like the Taiwan Night Market, demonstrating the versatile applications of its technology in creating culturally rich digital art.
Keynote Speeches by CEO Wesley Kuo
Cloud vs Console: The Future of Gaming Platforms
Highlighting Ubitus' involvement, CEO Wesley Kuo will take the stage as an official speaker at VivaTech. Wesley Kuo is scheduled to present on "Cloud vs Console: The Future of Gaming Platforms" on May 23, from 9:45 AM to 10:30 AM on Stage 2. His speech session with Michael Fan, partner of Galaxy Interactive, and Joe Tidy, Cyber Correspondent of BBC News will address crucial topics in the gaming industry, discussing the transformative potential of cloud technology over traditional console platforms, impacts on market dynamics, the benefits of subscription-based models, and the implications for data privacy and game diversity. For more details on the session, please visit: https://vivatechnology.com/sessions/4a3a33b1-f2f0-ee11-aaf0-000d3a2b945f.
Introduction to Ubitus' AI Solutions
In addition, Wesley Kuo will deliver a second presentation on the main stage in the TTA Pavilion(Booth D38) at 2 PM on the same day, focusing on Ubitus' AI-driven initiatives.
Ubitus' participation in VivaTech 2024 showcases its commitment to innovation and its role in shaping the future of digital entertainment and AI applications. By introducing AI solutions like Ubi-chan, who will engage visitors in French, and UbiArt, which captures the essence of local cultures, showcasing the vibrant Taiwanese food culture, Ubitus is set to make a significant impact at this global tech event.
Join us at Viva Technology 2024 to experience the future of technology with Ubitus' innovative solutions. We look forward to welcoming you to our booth and sharing our vision for a connected world. For more information, please visit Ubitus K.K. website.
About Ubitus K.K.
Ubitus K.K. is a technology company that specializes in cloud solutions, GPU virtualization technology, and cloud streaming platform. Our focus is on delivering exceptional cloud and artificial intelligence services.
Leveraging the power of GPUs, Ubitus has developed multiple AI solutions, including UbiGPT (Taiwan LLM), Ubi Anchor (AI anchor), Ubi-chan (AI character), and UbiArt (image generation software). Ubitus is committed to delivering tailor-made solutions designed to meet the diverse requirements of customers in various industries. Our goal is to seamlessly incorporate a range of AI applications into distinctive situations, ensuring a customized approach for each use case.
Ubitus’ cloud gaming solution enables users to enjoy AAA gaming experiences across devices with just an internet connection. Through our comprehensive Game Development Kit (GDK), we offer patented technology for rapid deployment, catering towards international clients that are interested in cloud gaming, including console gaming platforms, telecom operators, and game developers.
For Metaverse solutions, Ubitus possesses extensive global cloud deployment experience via GameCloud® technology offerings. Ubitus is able to stream interactive media content for platform operators and digital content developers on multi-devices, which offers users an immersive experience that accelerates metaverse popularization.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515534843/en/
Contact information
Ubitus K.K.
TEL :
+886-2-2717-6123 (Taipei)
+81-3-6435-3295 (Tokyo)
Media contact: pr@ubitus.net
Business inquiry: contact@ubitus.net
Website: www.ubitus.net
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease31.8.2024 17:00:00 CEST | Press release
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining a light on inequalities in treatment and outcomes experienced by various patient groups. The announcement follows the presentation of data from sub-analyses of the SANTORINI observational study and ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation) study programme, at the European Society of Cardiology (ESC) Congress 2024. Gender inequalities in CV disease treatment and LDL-C goal attainment Raised low-density lipoprotein cholesterol (LDL-C) is a key modifiable contributor to risk of cardiovascular major events. It has been shown that for every 1 mmol/L reduction in LDL-C, there is a 22% reduction in major cardiovascular events after 1 year.7,8 Female patients in Europe who are at high or very high CV risk were undertreated and less achieved guideline-recomm
Suzano completes purchase of 15% stake in Lenzing AG31.8.2024 00:40:00 CEST | Press release
Suzano, the world's largest pulp producer, today announces the completion of its acquisition of a 15% stake in Lenzing AG, the Vienna-listed leading global supplier of sustainable premium cellulosic fibres for the textile and non-wovens industry, from B&C Group. As announced in June this year, the transaction value is EUR 230 million (or EUR 39.70 per share). The agreement was subject to regulatory approval, which was granted without restrictions. The long-term partnership between Suzano and B&C Group establishes that Suzano has the right to hold two seats on Lenzing’s Board and the option to acquire an additional 15% stake from B&C Group until the end of 2028. Following the sale of the 15% stake, B&C Group now holds 37.25% of Lenzing’s share capital. Lenzing is a leading global supplier of premium wood-based cellulosic fibers (lyocell, modal, and viscose) for the production of clothing, home textiles, hygiene products, and non-woven materials. Beto Abreu, CEO of Suzano, said: “Lenzing
Ant International Collaborates with Brazilian Partners to Drive Financial Inclusion with Innovative Credit Tech Solutions30.8.2024 20:46:00 CEST | Press release
Ant International, a digital payment and financial technology leader, today announced its strategic initiative to provide AI-driven credit technology solutions designed to empower local partners and advance financial inclusions in Brazil. As a major milestone, Ant International has formed a strategic partnership with Dock, a leader in payments and banking technology in Latin America. This collaboration aims to enhance the credit management capability and infrastructure efficiency for Dock’s clients, which include financial institutions, retailers, fintech start-ups, etc. The shared vision is to make credit services more inclusive for market segments that are currently insufficiently served, such as micro, small and medium-sized enterprises (MSMEs). In the initial phase of the collaboration, Ant International’s AI-driven credit tech solutions, including an automated and intelligent risk management engine, will be explored for integration into Dock One platform. This initiative aims to s
Wipro Appoints Srikumar Rao as Global Head of Its Engineering Edge Business Line30.8.2024 16:20:00 CEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced the appointment of Srikumar Rao as Global Head of its Engineering Edge Business Line, effective from October 5, 2024. Srikumar succeeds Harmeet Chauhan, who is stepping down to pursue opportunities outside the organization. Srikumar will report to Srini Pallia. Srikumar has been with Wipro for 26 years and has grown with the organization, serving in various leadership roles. He was most recently the Chief Operating Officer (COO) of Wipro Engineering Edge (WEE) and Global Practice Head of Embedded Systems. His work has spanned several markets, selling and delivering specialized Engineering, Research, and Development (ER&D) services to Software & Internet, Semiconductor, Automotive, Manufacturing, and Communications clients. In his new role, Srikumar will continue to scale and strengthen Wipro’s engineering prowess. He will also be responsible for defining the vision
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress30.8.2024 12:00:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The data were presented today in a Hot Line session at the European Society of Cardiology (ESC) Congress 2024, taking place August 30-September 2 in London, United Kingdom. Results from the HELIOS-B study were also simultaneously published in TheNew England Journal of Medicine. As previously reported, the HELIOS-B study met all 10 of its primary and secondary endpoints, across both the overall and monotherapy populations, with statistical significance. Enrolled patients were predominantly New York Heart Association (NYHA) Class I or II with wild-type disease and had been diagnosed by non-invasive methods, with substantial concurrent treatment with available standard of care treatments such as tafamidis and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom